Clinical trials: Lung Diseases
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
- Trial name
- NCT00645788
- Testing
- Ciprofloxacin (Cipro Inhale, BAYQ3939)
- Where
- 86 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Bayer
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR…
- Trial name
- NCT02500927
- Testing
- ASP8273 Capsules, ASP8273 Capsules A
- Where
- 11 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Inc
Pneumonia, Bacterial
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years.
- Trial name
- NCT07428759
- Testing
- Pn-MAPS30plus, PCV20
- Where
- 2 sites in Australia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the effect on toxicity of the addition of CS 1008 to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects with stage IIIB wet or stage IV NSCLC.
- Trial name
- NCT00991796
- Testing
- CS-1008, Paclitaxel, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Daiichi Sankyo
Long COVID, Long COVID Syndrome
A Study to Examine Anktiva for the Treatment of COVID-19.
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
- Conditions
- Long COVID, Long COVID Syndrome, Long Covid 19
- Trial name
- NCT07123727
- Testing
- Anktiva
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Post Acute COVID-19 Syndrome, Long COVID
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
- Trial name
- NCT04949386
- Testing
- S-1226 (8%)
- Volunteers
- 48 people
- Sponsor
- SolAeroMed Inc.
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Carcinoma, Non-Small-Cell Lung
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or…
- Trial name
- NCT05663866
- Testing
- Dexamethasone, Montelukast, Methotrexate
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System
Collection of quantitative data to demonstrate the accuracy (bias) and precision (repeatability) of the Apieron INSIGHT(tm) eNO Breath System as compared to the FDA cleared NIOX eNO Breath System when testing is performed by…
- Trial name
- NCT00739531
- Testing
- Exhaled nitric oxide (eNO)
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Apieron
Pulmonary Disease, Chronic Obstructive
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently…
- Trial name
- NCT00388882
- Testing
- tiotropium, ipratropium bromide / albuterol
- Where
- 40 sites in United States, Argentina and 3 more
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus K drug as a first-line treatment of advanced non-small cell lung cancer.A total of 375 subjects will…
- Trial name
- NCT04964479
- Testing
- TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection
- Where
- 17 sites in China
- Volunteers
- 375 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Embolism
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Phase II trial of TS23
- Trial name
- NAIL-IT (NCT05408546)
- Testing
- TS23
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Translational Sciences, Inc.
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.
- Trial name
- NCT05305573
- Testing
- COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- Where
- 7 sites in Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Covid19
Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm
This study investigates the diagnostic performance of an AI algorithm in the detection of COVID-19 pneumonia on chest radiographs.
- Trial name
- NCT04561024
- Testing
- AI model
- Where
- Hong Kong
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ensemble Group Holdings, LLC
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC /VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478696
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 1 more
- Volunteers
- 732 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.